Oncology Institute | 10-Q: FY2025 Q3 Revenue: USD 136.56 M

LB filings
2025.11.13 21:48
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.

EPS: As of FY2025 Q3, the actual value is USD -0.14.

EBIT: As of FY2025 Q3, the actual value is USD -6.134 M.

Patient Services Segment

  • Revenue: $60,195 for the three months ended September 30, 2025, compared to $49,752 for the same period in 2024, representing a 21.0% increase. For the nine months ended September 30, 2025, revenue was $169,154, up from $154,666 in 2024, a 9.4% increase.
  • Direct Costs: $54,572 for the three months ended September 30, 2025, compared to $45,118 for the same period in 2024, a 21.0% increase. For the nine months ended September 30, 2025, direct costs were $152,802, up from $141,137 in 2024, an 8.3% increase.
  • Operating Income: $4,169 for the three months ended September 30, 2025, compared to $3,357 for the same period in 2024. For the nine months ended September 30, 2025, operating income was $11,939, compared to $10,518 in 2024.

Dispensary Segment

  • Revenue: $75,895 for the three months ended September 30, 2025, compared to $48,210 for the same period in 2024, a 57.4% increase. For the nine months ended September 30, 2025, revenue was $187,761, up from $132,329 in 2024, a 41.9% increase.
  • Direct Costs: $63,072 for the three months ended September 30, 2025, compared to $40,091 for the same period in 2024, a 57.3% increase. For the nine months ended September 30, 2025, direct costs were $154,021, up from $111,701 in 2024, a 37.9% increase.
  • Operating Income: $12,821 for the three months ended September 30, 2025, compared to $8,088 for the same period in 2024. For the nine months ended September 30, 2025, operating income was $33,732, compared to $20,536 in 2024.

Clinical Trials & Other Segment

  • Revenue: $474 for the three months ended September 30, 2025, compared to $1,939 for the same period in 2024, a 75.6% decrease. For the nine months ended September 30, 2025, revenue was $3,857, down from $6,150 in 2024, a 37.3% decrease.
  • Direct Costs: $0 for the three months ended September 30, 2025, compared to $326 for the same period in 2024. For the nine months ended September 30, 2025, direct costs were $279, down from $946 in 2024.
  • Operating Income: $474 for the three months ended September 30, 2025, compared to $1,558 for the same period in 2024. For the nine months ended September 30, 2025, operating income was $3,436, compared to $5,094 in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company has implemented initiatives to reduce costs and manage working capital more effectively, resulting in a 5% reduction in SG&A expenses compared to the prior year same quarter. The company expects to have sufficient liquidity to fund its operations for at least one year from the date of the financial statements.
  • Non-Core Business: The Clinical Trials segment is now operated by a third party under a profit-sharing arrangement, which has impacted revenue from this segment.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.